Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) shares gapped down prior to trading on Thursday . The stock had previously closed at $4.43, but opened at $4.29. Organogenesis shares last traded at $3.93, with a volume of 540,727 shares trading hands.
Organogenesis Stock Performance
The stock's 50-day moving average price is $2.97 and its 200-day moving average price is $2.81. The company has a market capitalization of $530.96 million, a price-to-earnings ratio of -62.33 and a beta of 1.60. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.42 and a current ratio of 2.73.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of ORGO. Verition Fund Management LLC grew its stake in Organogenesis by 542.8% in the 3rd quarter. Verition Fund Management LLC now owns 78,690 shares of the company's stock worth $225,000 after acquiring an additional 66,448 shares during the period. Captrust Financial Advisors purchased a new stake in shares of Organogenesis during the 3rd quarter valued at $36,000. FMR LLC grew its stake in shares of Organogenesis by 34.2% during the 3rd quarter. FMR LLC now owns 173,595 shares of the company's stock valued at $496,000 after buying an additional 44,199 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Organogenesis by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company's stock valued at $2,713,000 after buying an additional 23,675 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in shares of Organogenesis during the 3rd quarter valued at $43,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.
Organogenesis Company Profile
(
Get Free Report)
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Featured Articles
Before you consider Organogenesis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.
While Organogenesis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
